Cellular Therapeutics Ltd Information

Immetacyte Ltd (formally known as Cellular Therapeutics Ltd) is focused on developing patient specific immunotherapy, allowing the patient’s own immune system to be harnessed in order to fight cancers. Specifically the company is developing adoptive cell therapy (ACT) and has expertise in manufacturing and engineering of cells in a GMP compliant manner ready for patient infusion. The company, a spinout from the University of Manchester research group led by Professor Robert Hawkins and our team, has a track record of developing cell therapies with clinical success. Our strategy is to: • Develop the technology of cellular therapy manufacturing so it can be applied on a routine basis to large numbers of patients • Bring our own products to market